(H) Voltage-activated currents of PKD2-L1/PKD1-L3 channels. Averaged I-V curves with voltage steps from −80 mV to +80 mV in control bath (green) and 100 µM Gd 3+ (red) solutions, as compared to non-transfected HEK cells in control bath (black). Pipette solutions containing: 100 mM CsMeS, 35 mM NaCl, 10 mM HEPES, 5 mM EGTA, 2 mM MgCl 2 , at pH 7.4 adjusted with NaOH, were used to block K + channels endogenous to HEK Figure 3C . In HEK293 control cells, the fluorescence did not show any significant increase in response to acid withdrawal (middle), as summarized in Figure 3C . Other conditions:
V m =−60 mV and 5 mM EGTA included in pipettes. Figure 1A ) except that K + was removed from bath solutions. According to the equations in EXPERIMENTAL PROCEDURES, P Ca /P Na for PKD2-L1/PKD1-L3 channels was estimated to be 4.1 for this exemplar (E) and 5.3±0.7, n=10 in average (mean ± SEM). stimuli of all test levels did not induce any spike.
All above values are in mean ± SEM. In all above recordings, PKD1-L3 was co-expressed with different PKD2-L1 variants. All above values are in mean ± SEM.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Molecular Biology
We made point mutations, deletions, and FP--tagged constructs using standard molecular biological techniques.
We engineered the mPKD2--L1 variants as follows. For Figure 3 and Figure 5 , the pore--domain related point mutants including PKD2--L1_D523N, PKD2--L1_D525N, PKD2--L1_D523--N525N were achieved by QuikChange
Lightning Site--Directed Mutagenesis Kit (Agilent Technologies). After PCR reaction, the segments containing D523N and/or D525N was digested with two unique sites BspE I and BstE II and inserted this segment to replace the same region on the wt PKD2--L1 via these two unique sites. Also, for Figures 4--7 , the EF--hand related mutants including PKD2--L1_E613A, PKD2--L1_D643A, PKD2--L1_E613A--D643A, PKD2--L1_ΔEF1, PKD2--L1_ΔEF2 and PKD2--L1_ΔEF1--EF2 were achieved by the same strategy and use BspE I and EcoR I as the unique cloning sites.
To make FP--fusion constructs, mPKD2--L1 was amplified by PCR with flanking KpnI and NotI and cloned directionally via these two unique sites into pcDNA3 expressing plasmids. Then, EYFP was amplified with flanking NotI and XbaI and cloned via these two sites into pcDNA3, yielding 2L1--EYFP construct. Similar process was performed and RFP--2L1 and 1L3--EYFP were constructed in pcDNA3 plasmid. For Figure  6 , we cloned the human variants of hPKD2--L1_Liver and hPKD2--L1_Testis using hPKD2--L1_Kideny as the template.
hPKD2--L1_Liver was achieved by the same strategy used in EF--hand deletion mutants of mPKD2--L1, using BspEI and EcoRI as the unique cloning sites. For hPKD2--L1_Testis, it was amplified by PCR with anti--sense primer based on the difference between hPKD2--L1_Kidney and hPKD2--L1_Testis in their sequences of C--termini, also with flanking KpnI and NotI. Then the segment was cloned directionally via these two unique sites into pcDNA3 expressing plasmids. The anti--sense primer was as follows:
ATAAGAATGCGGCCGCCTAAGGCTTCCTCTTCTCTTTTATAGGGAACCTCACGCCTGGGGAGGGAGCCAG. CatCh was achieved by site--directed mutagenesis (L132C) with ChR2 as the template (Kleinlogel et al., 2011) . All segments subject to PCR or QuikChange were verified by sequencing.
Patch--clamp Electrophysiology
Electrodes were pulled with borosilicate glass capillaries by a programmable puller (P--1000, Sutter Instruments, USA) and heat--polished by a microforge (MF--900, Narishige, Japan), resulting in 1--3 MΩ resistances, before series resistance compensation of 80%. Whole--cell signals were low--pass filtered at 2 K--Hz or lower and digitized at higher rates (≥5 folds). The pipette solutions contained 140 mM KCl, 10 mM HEPES, and Ca 2+ buffers of 0.5 mM EGTA, 5 mM EGTA or 10 mM BAPTA respectively, at 290 mOsm, adjusted with glucose and at pH 7.4 adjusted with KOH. The extracellular solutions contained 134 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , 10 mM HEPES and 2 mM CaCl 2 , at ~300 mOsm adjusted with glucose and at pH 2.5 or 7.5 adjusted with HCl and NaOH.
For solutions containing 0, 10 mM or 100 mM CaCl 2 , NaCl was changed accordingly to 137 mM, 122 mM or 0.
For the pipette solutions with varying free [Ca 2+ ] (Figure  S5 ), the ratio of EGTA to total CaCl 2 was calculated by online website "Ca--EGTA Calculator" (http://web.stanford.edu/~cpatton/CaEGTA--TS.htm). To be more specific, for 10 μM free [Ca 2+ ], the pipette solution contained 2.11 mM EGTA, 2 mM CaCl 2 , 10 mM HEPES and 140 mM KCl and for 200 μM free [Ca 2+ ], the solution contained 2.11 mM EGTA, 2.3 mM CaCl 2 , 10 mM HEPES and 139 mM KCl.
As for 2 mM free [Ca 2+ ], the solution contained 2 mM CaCl 2 , 10 mM HEPES and 138 mM KCl. All of above pipette solutions were adjusted at 290 mOsm with glucose and at pH 7.4 with KOH.
Confocal Fluorescence Imaging
Experiments 
Calculations of Reversal Potentials and Permeability
We calculate reverse potential of Cl --(V rev, Cl ) in different extracellular solutions according to Nernst equation： (S1) 
